BellBrook Labs Market Research Report

Company Overview

• Name: BellBrook Labs

• Mission: BellBrook Labs is committed to accelerating enzyme-targeted drug discovery through enabling HTS assays. The company is passionate about modulating enzyme function to alleviate disease.

• Founded: 2002 by Robert Lowery, PhD.

• Key People:

• Robert Lowery, PhD - CEO

• Traci Pretsch - CFO

• Justin Brink - COO

• Headquarters: 1232 Fourier Drive, Suite 115, Madison, Wisconsin 53717 USA.

• Number of Employees: No information available.

• Revenue: No information available.

• Known For: BellBrook Labs is known for its Transcreener® and AptaFluor® HTS enzyme assays, which are the only HTS platforms for the direct detection of nucleotides. They are recognized for their contributions to enzyme-targeted drug discovery, particularly in cancer, metabolic and cardiovascular, autoimmune, and inflammatory disorders.

Products

1. Transcreener HTS Platform

• Description: A high-throughput screening (HTS) platform for direct detection of nucleotides produced by various enzymes.

• Key Features:

• Detects thousands of enzymes including kinases, ATPases, GTPases, and more.

• Offers continuous or endpoint assays.

• Mix-and-read single-step format.

2. AptaFluor

• Description: An assay for sensitive detection of methyltransferase activity using SAH detection.

• Key Features:

• High sensitivity for methyltransferase assay.

• Compatible with a wide range of methyltransferases.

• Employs SAH riboswitch for measuring enzyme activity.

3. Enzolution

• Description: A comprehensive enzyme assay solution designed for inhibitor discovery.

• Key Features:

• Includes validated enzymes, substrates, buffers, and detailed protocols.

• Designed for use with Transcreener and AptaFluor platforms.

4. Active Enzymes

• Description: Purified and highly active human enzymes validated for HTS assays.

• Key Features:

• Validated for high catalytic activity in various assays.

• Optimized for reliability in HTS settings.

Recent Developments

• New Products Launched: Introduction of the Enzolution™ HTS Enzyme Assays, a complete assay solution that includes validated recombinant enzymes and optimized protocols.

• New Features: Development of a novel AptaFluor assay for methyltransferase that utilizes a riboswitch to enhance sensitivity.

• Partnerships: Received National Institutes of Health (NIH) grants including a $1.8 million Phase II SBIR grant for developing drugs targeting the cGAS-STING pathway for lupus and related autoimmune diseases.

• Publications: BellBrook scientists published new research on the "Development and Validation of a Generic Methyltransferase Enzymatic Assay Based on an SAH Riboswitch" in SLAS Discovery journal.

• Conferences: Actively participates in prominent conferences such as SLAS 2025, where they exhibit cutting-edge HTS assay solutions.

Conclusion

BellBrook Labs stands out in the biochemical assay industry with its innovative products and scientific expertise. The company's dedication to developing high throughput screening tools underscores its commitment to advancing drug discovery and therapeutic solutions for challenging diseases. Through strategic product development and collaborative efforts, BellBrook Labs continues to push the boundaries in enzyme-targeted drug research.